2wd3: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==HIGHLY POTENT FIRST EXAMPLES OF DUAL AROMATASE-STEROID SULFATASE INHIBITORS BASED ON A BIPHENYL TEMPLATE== | |||
<StructureSection load='2wd3' size='340' side='right' caption='[[2wd3]], [[Resolution|resolution]] 1.80Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[2wd3]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2WD3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2WD3 FirstGlance]. <br> | |||
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=MS4:3-CHLORO-2-CYANO-5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)BIPHENYL-4-YL+SULFAMATE'>MS4</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene><br> | |||
<tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1okl|1okl]], [[1i9q|1i9q]], [[1zfq|1zfq]], [[1if7|1if7]], [[1cam|1cam]], [[1t9n|1t9n]], [[1cnw|1cnw]], [[1okn|1okn]], [[1f2w|1f2w]], [[1g52|1g52]], [[2h4n|2h4n]], [[1bnm|1bnm]], [[1cnh|1cnh]], [[1bnq|1bnq]], [[1ugc|1ugc]], [[1xev|1xev]], [[1ugg|1ugg]], [[1if9|1if9]], [[1g53|1g53]], [[1fqm|1fqm]], [[1ca2|1ca2]], [[1cal|1cal]], [[1fql|1fql]], [[1i9n|1i9n]], [[1g4o|1g4o]], [[2cba|2cba]], [[1ydc|1ydc]], [[1ccs|1ccs]], [[1lzv|1lzv]], [[1bnv|1bnv]], [[1fqr|1fqr]], [[1rzb|1rzb]], [[1a42|1a42]], [[1th9|1th9]], [[1zsb|1zsb]], [[1cnb|1cnb]], [[1hed|1hed]], [[1i8z|1i8z]], [[1g48|1g48]], [[1lg5|1lg5]], [[1bv3|1bv3]], [[1g0f|1g0f]], [[1tg3|1tg3]], [[1cvc|1cvc]], [[1ugd|1ugd]], [[1i90|1i90]], [[1yo0|1yo0]], [[1fsn|1fsn]], [[1hva|1hva]], [[1rze|1rze]], [[1ugb|1ugb]], [[1z9y|1z9y]], [[2fmz|2fmz]], [[1cnk|1cnk]], [[1bn1|1bn1]], [[1teq|1teq]], [[1rza|1rza]], [[2vvb|2vvb]], [[1ccu|1ccu]], [[1i9l|1i9l]], [[2cbc|2cbc]], [[1g46|1g46]], [[1cvb|1cvb]], [[1cao|1cao]], [[1fsq|1fsq]], [[6ca2|6ca2]], [[5ca2|5ca2]], [[1g1d|1g1d]], [[1caj|1caj]], [[1cvf|1cvf]], [[2fou|2fou]], [[1lgd|1lgd]], [[1if6|1if6]], [[1bn4|1bn4]], [[1teu|1teu]], [[1cra|1cra]], [[1ze8|1ze8]], [[1if4|1if4]], [[1hea|1hea]], [[1hca|1hca]], [[1cah|1cah]], [[1g4j|1g4j]], [[1raz|1raz]], [[1kwq|1kwq]], [[1cim|1cim]], [[1cvh|1cvh]], [[1if8|1if8]], [[1cin|1cin]], [[1i9m|1i9m]], [[1zfk|1zfk]], [[1fqn|1fqn]], [[1zsa|1zsa]], [[1lg6|1lg6]], [[1cnc|1cnc]], [[1bnn|1bnn]], [[1uga|1uga]], [[2foq|2foq]], [[1tb0|1tb0]], [[1cai|1cai]], [[2ax2|2ax2]], [[1dcb|1dcb]], [[1cnx|1cnx]], [[2hd6|2hd6]], [[5cac|5cac]], [[4cac|4cac]], [[1ttm|1ttm]], [[1cak|1cak]], [[1i9o|1i9o]], [[1cni|1cni]], [[1can|1can]], [[2eu3|2eu3]], [[1yda|1yda]], [[2wd2|2wd2]], [[1yo2|1yo2]], [[1eou|1eou]], [[1mua|1mua]], [[2ca2|2ca2]], [[1cct|1cct]], [[2abe|2abe]], [[1oq5|1oq5]], [[1rzc|1rzc]], [[1ugf|1ugf]], [[2cbe|2cbe]], [[1thk|1thk]], [[1kwr|1kwr]], [[1zgf|1zgf]], [[1cay|1cay]], [[1moo|1moo]], [[1cng|1cng]], [[1hec|1hec]], [[2ez7|2ez7]], [[8ca2|8ca2]], [[9ca2|9ca2]], [[1fr7|1fr7]], [[1zh9|1zh9]], [[1ydd|1ydd]], [[1bic|1bic]], [[1lug|1lug]], [[1caz|1caz]], [[1cvd|1cvd]], [[7ca2|7ca2]], [[1fr4|1fr4]], [[1cil|1cil]], [[4ca2|4ca2]], [[2geh|2geh]], [[1g45|1g45]], [[1ydb|1ydb]], [[1dca|1dca]], [[1fsr|1fsr]], [[2cbb|2cbb]], [[1i9p|1i9p]], [[12ca|12ca]], [[1avn|1avn]], [[1bcd|1bcd]], [[1am6|1am6]], [[1i91|1i91]], [[1cve|1cve]], [[1g3z|1g3z]], [[1heb|1heb]], [[2cbd|2cbd]], [[1zsc|1zsc]], [[3ca2|3ca2]], [[1bnu|1bnu]], [[1zge|1zge]], [[1bnw|1bnw]], [[2fov|2fov]], [[1te3|1te3]], [[1bnt|1bnt]], [[1if5|1if5]], [[1yo1|1yo1]], [[1rzd|1rzd]], [[1g54|1g54]], [[1uge|1uge]], [[1g0e|1g0e]], [[2fmg|2fmg]], [[1ray|1ray]], [[1cva|1cva]], [[1ca3|1ca3]], [[2eu2|2eu2]], [[1tg9|1tg9]], [[1tbt|1tbt]], [[1xeg|1xeg]], [[1bn3|1bn3]], [[1okm|1okm]], [[1cny|1cny]], [[1cnj|1cnj]], [[1h9n|1h9n]], [[2vva|2vva]], [[2aw1|2aw1]], [[1h4n|1h4n]], [[2fos|2fos]], [[1h9q|1h9q]]</td></tr> | |||
<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Carbonate_dehydratase Carbonate dehydratase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=4.2.1.1 4.2.1.1] </span></td></tr> | |||
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2wd3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2wd3 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2wd3 RCSB], [http://www.ebi.ac.uk/pdbsum/2wd3 PDBsum]</span></td></tr> | |||
<table> | |||
== Disease == | |||
[[http://www.uniprot.org/uniprot/CAH2_HUMAN CAH2_HUMAN]] Defects in CA2 are the cause of osteopetrosis autosomal recessive type 3 (OPTB3) [MIM:[http://omim.org/entry/259730 259730]]; also known as osteopetrosis with renal tubular acidosis, carbonic anhydrase II deficiency syndrome, Guibaud-Vainsel syndrome or marble brain disease. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB3 is associated with renal tubular acidosis, cerebral calcification (marble brain disease) and in some cases with mental retardation.<ref>PMID:1928091</ref> <ref>PMID:1542674</ref> <ref>PMID:8834238</ref> <ref>PMID:9143915</ref> <ref>PMID:15300855</ref> | |||
== Function == | |||
[[http://www.uniprot.org/uniprot/CAH2_HUMAN CAH2_HUMAN]] Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye.<ref>PMID:10550681</ref> <ref>PMID:11831900</ref> | |||
== Evolutionary Conservation == | |||
[[Image:Consurf_key_small.gif|200px|right]] | |||
Check<jmol> | |||
<jmolCheckbox> | |||
<scriptWhenChecked>select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/wd/2wd3_consurf.spt"</scriptWhenChecked> | |||
<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | |||
<text>to colour the structure by Evolutionary Conservation</text> | |||
</jmolCheckbox> | |||
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/chain_selection.php?pdb_ID=2ata ConSurf]. | |||
<div style="clear:both"></div> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Single agents against multiple drug targets are of increasing interest. Hormone-dependent breast cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS). The aromatase inhibitory pharmacophore was thus introduced into a known biphenyl STS inhibitor to give a series of novel dual aromatase-sulfatase inhibitors (DASIs). Several compounds are good aromatase or STS inhibitors and DASI 20 (IC(50): aromatase, 2.0 nM; STS, 35 nM) and its chlorinated congener 23 (IC(50): aromatase, 0.5 nM; STS, 5.5 nM) are examples that show exceptional dual potency in JEG-3 cells. Both biphenyls share a para-sulfamate-containing ring B and a ring A, which contains a triazol-1-ylmethyl meta to the biphenyl bridge and para to a nitrile. At 1 mg/kg po, 20 and 23 reduced plasma estradiol levels strongly and inhibited liver STS activity potently in vivo. 23 is nonestrogenic and potently inhibits carbonic anhydrase II (IC(50) 86 nM). A complex was crystallized and its structure was solved by X-ray crystallography. This class of DASI should encourage further development toward multitargeted therapeutic intervention in HDBC. | |||
Highly Potent First Examples of Dual Aromatase-Steroid Sulfatase Inhibitors based on a Biphenyl Template (dagger).,Woo LW, Jackson T, Putey A, Cozier G, Leonard P, Acharya KR, Chander SK, Purohit A, Reed MJ, Potter BV J Med Chem. 2010 Feb 11. PMID:20148564<ref>PMID:20148564</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
==See Also== | ==See Also== | ||
*[[Carbonic anhydrase|Carbonic anhydrase]] | *[[Carbonic anhydrase|Carbonic anhydrase]] | ||
== References == | |||
== | <references/> | ||
__TOC__ | |||
</StructureSection> | |||
[[Category: Carbonate dehydratase]] | [[Category: Carbonate dehydratase]] | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] |
Revision as of 04:20, 1 October 2014
HIGHLY POTENT FIRST EXAMPLES OF DUAL AROMATASE-STEROID SULFATASE INHIBITORS BASED ON A BIPHENYL TEMPLATEHIGHLY POTENT FIRST EXAMPLES OF DUAL AROMATASE-STEROID SULFATASE INHIBITORS BASED ON A BIPHENYL TEMPLATE
Structural highlightsDisease[CAH2_HUMAN] Defects in CA2 are the cause of osteopetrosis autosomal recessive type 3 (OPTB3) [MIM:259730]; also known as osteopetrosis with renal tubular acidosis, carbonic anhydrase II deficiency syndrome, Guibaud-Vainsel syndrome or marble brain disease. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB3 is associated with renal tubular acidosis, cerebral calcification (marble brain disease) and in some cases with mental retardation.[1] [2] [3] [4] [5] Function[CAH2_HUMAN] Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye.[6] [7] Evolutionary Conservation![]() Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedSingle agents against multiple drug targets are of increasing interest. Hormone-dependent breast cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS). The aromatase inhibitory pharmacophore was thus introduced into a known biphenyl STS inhibitor to give a series of novel dual aromatase-sulfatase inhibitors (DASIs). Several compounds are good aromatase or STS inhibitors and DASI 20 (IC(50): aromatase, 2.0 nM; STS, 35 nM) and its chlorinated congener 23 (IC(50): aromatase, 0.5 nM; STS, 5.5 nM) are examples that show exceptional dual potency in JEG-3 cells. Both biphenyls share a para-sulfamate-containing ring B and a ring A, which contains a triazol-1-ylmethyl meta to the biphenyl bridge and para to a nitrile. At 1 mg/kg po, 20 and 23 reduced plasma estradiol levels strongly and inhibited liver STS activity potently in vivo. 23 is nonestrogenic and potently inhibits carbonic anhydrase II (IC(50) 86 nM). A complex was crystallized and its structure was solved by X-ray crystallography. This class of DASI should encourage further development toward multitargeted therapeutic intervention in HDBC. Highly Potent First Examples of Dual Aromatase-Steroid Sulfatase Inhibitors based on a Biphenyl Template (dagger).,Woo LW, Jackson T, Putey A, Cozier G, Leonard P, Acharya KR, Chander SK, Purohit A, Reed MJ, Potter BV J Med Chem. 2010 Feb 11. PMID:20148564[8] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|